Edition:
United States

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

58.45USD
15 Dec 2017
Change (% chg)

$-0.95 (-1.60%)
Prev Close
$59.40
Open
$59.50
Day's High
$60.15
Day's Low
$58.00
Volume
470,787
Avg. Vol
63,753
52-wk High
$70.75
52-wk Low
$17.15

Latest Key Developments (Source: Significant Developments)

Foundation Medicine Q3 loss per share $0.90
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 third quarter results and recent highlights.Q3 loss per share $0.90.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $42.7 million versus I/B/E/S view $38 million.Q3 earnings per share view $-1.10 -- Thomson Reuters I/B/E/S.  Full Article

Foundation Medicine receives approval from state of New York for foundation act liquid biopsy assay
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Foundation Medicine Inc : :Foundation Medicine Inc - receives approval from state of New York for foundation act liquid biopsy assay.  Full Article

Foundation Medicine and Roche enters into a fifth amendment to Collaboration Agreement
Wednesday, 13 Sep 2017 04:49pm EDT 

Sept 13 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - On September 8, company and Roche entered into a fifth amendment to Collaboration Agreement - SEC filing.Foundation Medicine Inc- Amendment reduced certain exclusivity provisions relating to blood-based tumor mutational burden assays.  Full Article

Foundation Medicine entered into amendment letter agreement with Roche Finance
Tuesday, 1 Aug 2017 04:36pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - co entered into amendment letter agreement with Roche Finance Ltd amending credit facility agreement, dated August 2, 2016.Foundation Medicine - amendment amends existing credit facility to provide for extension of period during which co may borrow funds from 3 to 4 yrs.Foundation Medicine Inc - amendment increases available funds from $100 million to $200 million - SEC filing.  Full Article

Foundation Medicine Q2 revenue $35 mln
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 second quarter results and recent highlights.Q2 loss per share $1.24.Q2 revenue $35 million versus I/B/E/S view $34.9 million.Sees FY 2017 revenue $135 million to $145 million.Q2 earnings per share view $-1.11 -- Thomson Reuters I/B/E/S.Foundation Medicine Inc - company is increasing clinical volume guidance and now expects to deliver between 61,000 and 64,000 clinical tests in 2017.Foundation Medicine Inc - increasing operating expenses and now expects they will be in range of $215 million and $225 million for 2017.FY 2017 revenue view $138.2 million -- Thomson Reuters I/B/E/S.  Full Article

Kura Oncology ‍enters into collaboration agreement with Foundation Medicine ​
Thursday, 13 Jul 2017 07:30am EDT 

July 13 (Reuters) - Foundation Medicine Inc -:Kura Oncology Inc - ‍entered into a collaboration agreement with Foundation Medicine, Inc.​.Kura Oncology Inc - collaboration to support patient enrollment for co's clinical program for tipifarnib.  Full Article

Foundation Medicine announces Q1 revenue $26.3 million
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 first quarter results and recent highlights.Q1 loss per share $1.31.Sees FY 2017 revenue $135 million to $145 million.Q1 revenue $26.3 million versus I/B/E/S view $29.1 million.Q1 earnings per share view $-1.01 -- Thomson Reuters I/B/E/S.Foundation Medicine Inc says Foundation Medicine's business and financial outlook for 2017 remains unchanged.  Full Article

Foundation Medicine Q4 loss per share $1.02
Wednesday, 22 Feb 2017 04:01pm EST 

Foundation Medicine Inc : Foundation Medicine announces 2016 fourth quarter and year-end results, recent highlights and 2017 outlook . Sees FY 2017 revenue $135 million to $145 million . Q4 revenue $28.8 million versus I/B/E/S view $29.2 million . Q4 loss per share $1.02 . Q4 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S . Foundation Medicine Inc says company expects to deliver between 53,000 and 56,000 clinical tests in 2017 . Company expects operating expenses will be in range of $205 million to $215 million in 2017 .FY2017 revenue view $147.8 million -- Thomson Reuters I/B/E/S.  Full Article

Foundation Medicine reports preliminary 2016 results
Monday, 9 Jan 2017 06:30am EST 

Foundation Medicine Inc : Foundation Medicine reports preliminary 2016 results .Preliminary unaudited total revenue of approximately $28.8 million in Q4 of 2016.  Full Article

Foundation Medicine Inc - FoundationOne accepted by FDA and CMS for Parallel Review and FDA Expedited Access Pathway
Tuesday, 2 Aug 2016 04:00pm EDT 

Foundation Medicine Inc : FoundationOne® accepted by FDA and CMS for parallel review and FDA expedited access pathway . FDA also accepted foundation medicine's request for review as part of its Expedited Access Pathway (EAP) for breakthrough devices .Foundation Medicine Inc says based on discussions with FDA and CMS, Foundation Medicine believes parallel review will conclude in second half of 2017.  Full Article

Foundation's cancer gene test gets U.S. FDA and Medicare nod

CHICAGO A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.